DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for dystocia — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDystocia maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for dystocia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
oxytocin receptor (OXTR) — OXTR is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 3~{r},6~{r}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6TPK · 3.2 Å · ligand (3~{R},6~{R})-6-[(2~{S})-butan-2-yl]-3-(2,3-dihydro-1~{H}-inden-2-yl)-1-[(1~{R})-1-(2-methyl-1,3-oxazol-4-yl)-2-morpholin-4-yl-2-oxidanylidene-ethyl]piperazine-2,5-dione (NU2). Experimental structure, not a prediction.
What the evidence adds up to
In a retrospective case-control study of 598 term primiparous women, 296 whose intended vaginal delivery ended in acute caesarean section for dystocia were compared with 302 who had a successful vaginal delivery. Women in the dystocia group were older (odds ratio 1.06 per year), shorter (OR 0.94 per cm), and more often had a chronic disease (OR 1.60). Fetal malposition (OR 42.0) and chorioamnionitis (OR 10.9) were far more common in the dystocia group, labour was less often in the active phase on arrival (OR 3.37), and cervical dilatation was less advanced (1.5 cm vs 2.5 cm, OR 0.57). Pre-pregnancy body mass index was higher in the dystocia group (24.1 vs 22.6 kg/m²), and each 1 kg/m² increase in BMI raised the risk of caesarean for dystocia by 10%. Severely obese women (BMI ≥ 35) had labours four hours longer than normal-weight women. The authors conclude that labour dystocia is multifactorial and that the possibility to ameliorate the condition via medical treatment is limited.
A 1987 review of cellular and molecular bases for dystocia describes myogenic mechanisms and emphasises studies of gap junctions between myometrial cells. The review states that specific physiologic mechanisms regulate structural and functional coupling of myometrial cells during labour, and that integration of these control mechanisms probably ensures appropriate activation and maintenance of synchronous contractility for effective delivery. No clinical data or interventions are reported in this review.
A 2016 practical guide to managing dystocia in the whelping bitch offers advice on interventions and preparation but provides no quantitative clinical results, no sample sizes, and no outcome data. The guide focuses on clinician confidence and client communication.
What is still missing: no drug or medical treatment for dystocia in humans is tested or recommended in these abstracts. No randomised trial of any intervention for dystocia is reported. The human study is retrospective and cannot establish causation. The cellular review is decades old and does not translate into a clinical therapy. The veterinary guide offers no evidence base. There is no funded trial of a drug to prevent or treat dystocia, no validated patient stratification beyond BMI and cervical status, and no molecular target that has been tested in a controlled human study.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
BMC Pregnancy and Childbirth · 2018 · 34 citations · open access
Impact of obesity and other risk factors on labor dystocia in term primiparous women: a case control study
AbstractPurpose of this study was to investigate differences between primiparous term pregnancies, one leading to vaginal delivery (VD) and the other to acute cesarean section (CS) due to labor dystocia in the first stage of labor. We particularly wanted to assess the influence of body mass index (BMI) on CS risk. A retrospective case-control study in a tertiary delivery unit with 5200 deliveries annually. Cases were 296 term primiparous women whose intended vaginal labor ended in acute CS because of dystocia. Controls were primiparas with successful vaginal delivery VD ( n = 302). The data were retrieved from medical records. Multiple logistic regression analyses were used to assess the associations between BMI and covariates on labor dystocia. In the cases ending with acute CS, women were older (OR 1.06 [1.03–1.10]), shorter (OR 0.94 [0.91–0.96]) and more often had a chronic disease (OR 1.60 [1.1–2.29]). In this group fetal malposition (OR 42.0 [19.2–91.9]) and chorioamnionitis (OR 10.9 [5.01–23.6]) were more common, labor was less often in an active phase (OR 3.37 [2.38–4.76]) and the cervix was not as well ripened (1.5 vs. 2.5 cm, OR 0.57 [0.48–0.67] on arrival at the birth unit. BMI was higher in the dystocia group (24.1 vs. 22.6 kg/m 2 , p < 0.001), and rising maternal pre-pregnancy BMI had a strong association with dystocia risk. If BMI increased by 1 kg/m 2 , the risk of CS was 10% elevated. Among obese primiparas, premature rupture of membranes, chorioamnionitis and induction of labor were more common. Their labors were less often in an active phase at hospital admission. Severely obese primiparas (BMI ≥ 35 kg/m 2 ) had 4 hours longer labor than normal-weight parturients. Labor dystocia is a multifactorial phenomenon in which the possibility to ameliorate the condition via medical treatment is limited. Hospital admission at an advanced stage of labor is recommended. Pre-pregnancy weight control in the population at reproductive age is essential, as a high BMI is strongly associated with labor dystocia.
AbstractIn this review I have briefly outlined some of the cellular and molecular reasons for dystocia. I have described the myogenic, that may control the normal progression of labor and explain inadequate uterine contractility associated with dystocia. I have placed particular emphasis on our studies of gap junctions and their regulation. These studies show that there are specific physiologic mechanisms for regulating structural and functional coupling between myometrial cells during labor. The integration of these control mechanisms probably operates to ensure appropriate activation and maintenance of synchronous contractility of the myometrium and effective delivery.
A practical guide to management of dystocia in the whelping bitch
AbstractManaging a whelping in practice can be daunting to even the most experienced of clinicians. This article aims to give practical advice regarding interventions in a potentially stressful situation, particularly regarding the management of the bitch with dystocia. Preparation is the key, be it practically in the surgery or in the knowledge of what to expect when. If you are confident in what you are doing then client/breeder will have confidence in you.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
